Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
Drugs for Transthyretin Amyloid Cardiomyopathy(ATTR-CM)refer to medications specifically used to treat the condition characterized by the abnormal deposition of transthyretin(TTR)protein in cardiac tissues,leading to progressive cardiomyopathy and heart failure.These drugs collectively aim to stabilize TTR,reduce amyloid deposition,manage symptoms,and improve cardiac function in patients with ATTR-CM.
The global Drugs for Transthyretin Amyloid Cardiomyopathy market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Drugs for Transthyretin Amyloid Cardiomyopathy Industry Forecast” looks at past sales and reviews total world Drugs for Transthyretin Amyloid Cardiomyopathy sales in 2023, providing a comprehensive analysis by region and market sector of projected Drugs for Transthyretin Amyloid Cardiomyopathy sales for 2024 through 2030. With Drugs for Transthyretin Amyloid Cardiomyopathy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drugs for Transthyretin Amyloid Cardiomyopathy industry.
This Insight Report provides a comprehensive analysis of the global Drugs for Transthyretin Amyloid Cardiomyopathy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drugs for Transthyretin Amyloid Cardiomyopathy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drugs for Transthyretin Amyloid Cardiomyopathy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs for Transthyretin Amyloid Cardiomyopathy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs for Transthyretin Amyloid Cardiomyopathy.
United States market for Drugs for Transthyretin Amyloid Cardiomyopathy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Drugs for Transthyretin Amyloid Cardiomyopathy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Drugs for Transthyretin Amyloid Cardiomyopathy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Drugs for Transthyretin Amyloid Cardiomyopathy players cover Pfizer, Teva, Avet Pharmaceuticals, Zydus Pharms, Alnylam Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Transthyretin Amyloid Cardiomyopathy market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Drugs for Transthyretin Amyloid Cardiomyopathy market?
What factors are driving Drugs for Transthyretin Amyloid Cardiomyopathy market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Drugs for Transthyretin Amyloid Cardiomyopathy market opportunities vary by end market size?
How does Drugs for Transthyretin Amyloid Cardiomyopathy break out by Type, by Application?
Drugs for Transthyretin Amyloid Cardiomyopathy(ATTR-CM)refer to medications specifically used to treat the condition characterized by the abnormal deposition of transthyretin(TTR)protein in cardiac tissues,leading to progressive cardiomyopathy and heart failure.These drugs collectively aim to stabilize TTR,reduce amyloid deposition,manage symptoms,and improve cardiac function in patients with ATTR-CM.
The global Drugs for Transthyretin Amyloid Cardiomyopathy market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Drugs for Transthyretin Amyloid Cardiomyopathy Industry Forecast” looks at past sales and reviews total world Drugs for Transthyretin Amyloid Cardiomyopathy sales in 2023, providing a comprehensive analysis by region and market sector of projected Drugs for Transthyretin Amyloid Cardiomyopathy sales for 2024 through 2030. With Drugs for Transthyretin Amyloid Cardiomyopathy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drugs for Transthyretin Amyloid Cardiomyopathy industry.
This Insight Report provides a comprehensive analysis of the global Drugs for Transthyretin Amyloid Cardiomyopathy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drugs for Transthyretin Amyloid Cardiomyopathy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drugs for Transthyretin Amyloid Cardiomyopathy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs for Transthyretin Amyloid Cardiomyopathy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs for Transthyretin Amyloid Cardiomyopathy.
United States market for Drugs for Transthyretin Amyloid Cardiomyopathy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Drugs for Transthyretin Amyloid Cardiomyopathy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Drugs for Transthyretin Amyloid Cardiomyopathy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Drugs for Transthyretin Amyloid Cardiomyopathy players cover Pfizer, Teva, Avet Pharmaceuticals, Zydus Pharms, Alnylam Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Transthyretin Amyloid Cardiomyopathy market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Transthyretin Tetramer Stabilizer
- RNA Interference
- Antisense Oligonucleotides
- Other
- Hospital and Clinic
- Retail Pharmacies
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Teva
- Avet Pharmaceuticals
- Zydus Pharms
- Alnylam Pharmaceuticals
- Akcea Therapeutics
- Ionis Pharmaceuticals
- Qilu pharmaceutical
- Chia Tai Tianqing Pharmaceutical
- Luoxin Pharmaceutical
- Zhengzhou Taifeng Pharmaceutical
- Shapuaisi Pharma
- Tonghua Zhongsheng Pharmaceutical
What is the 10-year outlook for the global Drugs for Transthyretin Amyloid Cardiomyopathy market?
What factors are driving Drugs for Transthyretin Amyloid Cardiomyopathy market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Drugs for Transthyretin Amyloid Cardiomyopathy market opportunities vary by end market size?
How does Drugs for Transthyretin Amyloid Cardiomyopathy break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Drugs for Transthyretin Amyloid Cardiomyopathy by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Drugs for Transthyretin Amyloid Cardiomyopathy by Country/Region, 2019, 2023 & 2030
2.2 Drugs for Transthyretin Amyloid Cardiomyopathy Segment by Type
2.2.1 Transthyretin Tetramer Stabilizer
2.2.2 RNA Interference
2.2.3 Antisense Oligonucleotides
2.2.4 Other
2.3 Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type
2.3.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Type (2019-2024)
2.3.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue and Market Share by Type (2019-2024)
2.3.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sale Price by Type (2019-2024)
2.4 Drugs for Transthyretin Amyloid Cardiomyopathy Segment by Application
2.4.1 Hospital and Clinic
2.4.2 Retail Pharmacies
2.4.3 Other
2.5 Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application
2.5.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sale Market Share by Application (2019-2024)
2.5.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue and Market Share by Application (2019-2024)
2.5.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Breakdown Data by Company
3.1.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Annual Sales by Company (2019-2024)
3.1.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Company (2019-2024)
3.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Annual Revenue by Company (2019-2024)
3.2.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Company (2019-2024)
3.2.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Company (2019-2024)
3.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sale Price by Company
3.4 Key Manufacturers Drugs for Transthyretin Amyloid Cardiomyopathy Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Drugs for Transthyretin Amyloid Cardiomyopathy Product Location Distribution
3.4.2 Players Drugs for Transthyretin Amyloid Cardiomyopathy Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DRUGS FOR TRANSTHYRETIN AMYLOID CARDIOMYOPATHY BY GEOGRAPHIC REGION
4.1 World Historic Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Geographic Region (2019-2024)
4.1.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Country/Region (2019-2024)
4.2.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Annual Sales by Country/Region (2019-2024)
4.2.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Annual Revenue by Country/Region (2019-2024)
4.3 Americas Drugs for Transthyretin Amyloid Cardiomyopathy Sales Growth
4.4 APAC Drugs for Transthyretin Amyloid Cardiomyopathy Sales Growth
4.5 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales Growth
4.6 Middle East & Africa Drugs for Transthyretin Amyloid Cardiomyopathy Sales Growth
5 AMERICAS
5.1 Americas Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country
5.1.1 Americas Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2019-2024)
5.1.2 Americas Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country (2019-2024)
5.2 Americas Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2019-2024)
5.3 Americas Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region
6.1.1 APAC Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region (2019-2024)
6.1.2 APAC Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Region (2019-2024)
6.2 APAC Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2019-2024)
6.3 APAC Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Drugs for Transthyretin Amyloid Cardiomyopathy by Country
7.1.1 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2019-2024)
7.1.2 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country (2019-2024)
7.2 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2019-2024)
7.3 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Drugs for Transthyretin Amyloid Cardiomyopathy by Country
8.1.1 Middle East & Africa Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2019-2024)
8.1.2 Middle East & Africa Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country (2019-2024)
8.2 Middle East & Africa Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2019-2024)
8.3 Middle East & Africa Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Drugs for Transthyretin Amyloid Cardiomyopathy
10.3 Manufacturing Process Analysis of Drugs for Transthyretin Amyloid Cardiomyopathy
10.4 Industry Chain Structure of Drugs for Transthyretin Amyloid Cardiomyopathy
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Drugs for Transthyretin Amyloid Cardiomyopathy Distributors
11.3 Drugs for Transthyretin Amyloid Cardiomyopathy Customer
12 WORLD FORECAST REVIEW FOR DRUGS FOR TRANSTHYRETIN AMYLOID CARDIOMYOPATHY BY GEOGRAPHIC REGION
12.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Size Forecast by Region
12.1.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Forecast by Region (2025-2030)
12.1.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Drugs for Transthyretin Amyloid Cardiomyopathy Forecast by Type (2025-2030)
12.7 Global Drugs for Transthyretin Amyloid Cardiomyopathy Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.1.3 Pfizer Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Teva
13.2.1 Teva Company Information
13.2.2 Teva Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.2.3 Teva Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Teva Main Business Overview
13.2.5 Teva Latest Developments
13.3 Avet Pharmaceuticals
13.3.1 Avet Pharmaceuticals Company Information
13.3.2 Avet Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.3.3 Avet Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Avet Pharmaceuticals Main Business Overview
13.3.5 Avet Pharmaceuticals Latest Developments
13.4 Zydus Pharms
13.4.1 Zydus Pharms Company Information
13.4.2 Zydus Pharms Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.4.3 Zydus Pharms Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Zydus Pharms Main Business Overview
13.4.5 Zydus Pharms Latest Developments
13.5 Alnylam Pharmaceuticals
13.5.1 Alnylam Pharmaceuticals Company Information
13.5.2 Alnylam Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.5.3 Alnylam Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Alnylam Pharmaceuticals Main Business Overview
13.5.5 Alnylam Pharmaceuticals Latest Developments
13.6 Akcea Therapeutics
13.6.1 Akcea Therapeutics Company Information
13.6.2 Akcea Therapeutics Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.6.3 Akcea Therapeutics Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Akcea Therapeutics Main Business Overview
13.6.5 Akcea Therapeutics Latest Developments
13.7 Ionis Pharmaceuticals
13.7.1 Ionis Pharmaceuticals Company Information
13.7.2 Ionis Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.7.3 Ionis Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Ionis Pharmaceuticals Main Business Overview
13.7.5 Ionis Pharmaceuticals Latest Developments
13.8 Qilu pharmaceutical
13.8.1 Qilu pharmaceutical Company Information
13.8.2 Qilu pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.8.3 Qilu pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Qilu pharmaceutical Main Business Overview
13.8.5 Qilu pharmaceutical Latest Developments
13.9 Chia Tai Tianqing Pharmaceutical
13.9.1 Chia Tai Tianqing Pharmaceutical Company Information
13.9.2 Chia Tai Tianqing Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.9.3 Chia Tai Tianqing Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
13.9.5 Chia Tai Tianqing Pharmaceutical Latest Developments
13.10 Luoxin Pharmaceutical
13.10.1 Luoxin Pharmaceutical Company Information
13.10.2 Luoxin Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.10.3 Luoxin Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Luoxin Pharmaceutical Main Business Overview
13.10.5 Luoxin Pharmaceutical Latest Developments
13.11 Zhengzhou Taifeng Pharmaceutical
13.11.1 Zhengzhou Taifeng Pharmaceutical Company Information
13.11.2 Zhengzhou Taifeng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.11.3 Zhengzhou Taifeng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Zhengzhou Taifeng Pharmaceutical Main Business Overview
13.11.5 Zhengzhou Taifeng Pharmaceutical Latest Developments
13.12 Shapuaisi Pharma
13.12.1 Shapuaisi Pharma Company Information
13.12.2 Shapuaisi Pharma Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.12.3 Shapuaisi Pharma Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Shapuaisi Pharma Main Business Overview
13.12.5 Shapuaisi Pharma Latest Developments
13.13 Tonghua Zhongsheng Pharmaceutical
13.13.1 Tonghua Zhongsheng Pharmaceutical Company Information
13.13.2 Tonghua Zhongsheng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.13.3 Tonghua Zhongsheng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Tonghua Zhongsheng Pharmaceutical Main Business Overview
13.13.5 Tonghua Zhongsheng Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Drugs forTransthyretin Amyloid Cardiomyopathy Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Drugs forTransthyretin Amyloid Cardiomyopathy Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players ofTransthyretinTetramer Stabilizer
Table 4. Major Players of RNA Interference
Table 5. Major Players of Antisense Oligonucleotides
Table 6. Major Players of Other
Table 7. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales byType (2019-2024) & (K Units)
Table 8. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share byType (2019-2024)
Table 9. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue byType (2019-2024) & ($ million)
Table 10. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share byType (2019-2024)
Table 11. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sale Price byType (2019-2024) & (US$/Unit)
Table 12. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sale by Application (2019-2024) & (K Units)
Table 13. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sale Market Share by Application (2019-2024)
Table 14. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue by Application (2019-2024) & ($ million)
Table 15. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Application (2019-2024)
Table 16. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sale Price by Application (2019-2024) & (US$/Unit)
Table 17. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Company (2019-2024) & (K Units)
Table 18. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Company (2019-2024)
Table 19. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue by Company (2019-2024) & ($ millions)
Table 20. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Company (2019-2024)
Table 21. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sale Price by Company (2019-2024) & (US$/Unit)
Table 22. Key Manufacturers Drugs forTransthyretin Amyloid Cardiomyopathy Producing Area Distribution and Sales Area
Table 23. Players Drugs forTransthyretin Amyloid Cardiomyopathy Products Offered
Table 24. Drugs forTransthyretin Amyloid Cardiomyopathy Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Geographic Region (2019-2024) & (K Units)
Table 28. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share Geographic Region (2019-2024)
Table 29. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Geographic Region (2019-2024)
Table 31. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Country/Region (2019-2024) & (K Units)
Table 32. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Country/Region (2019-2024)
Table 33. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Country/Region (2019-2024)
Table 35. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Country (2019-2024) & (K Units)
Table 36. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Country (2019-2024)
Table 37. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Revenue by Country (2019-2024) & ($ millions)
Table 38. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Sales byType (2019-2024) & (K Units)
Table 39. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Application (2019-2024) & (K Units)
Table 40. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Region (2019-2024) & (K Units)
Table 41. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Region (2019-2024)
Table 42. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Revenue by Region (2019-2024) & ($ millions)
Table 43. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Sales byType (2019-2024) & (K Units)
Table 44. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Application (2019-2024) & (K Units)
Table 45. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Country (2019-2024) & (K Units)
Table 46. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Revenue by Country (2019-2024) & ($ millions)
Table 47. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Sales byType (2019-2024) & (K Units)
Table 48. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Application (2019-2024) & (K Units)
Table 49. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Country (2019-2024) & (K Units)
Table 50. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Country (2019-2024)
Table 51. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Sales byType (2019-2024) & (K Units)
Table 52. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Application (2019-2024) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Drugs forTransthyretin Amyloid Cardiomyopathy
Table 54. Key Market Challenges & Risks of Drugs forTransthyretin Amyloid Cardiomyopathy
Table 55. Key IndustryTrends of Drugs forTransthyretin Amyloid Cardiomyopathy
Table 56. Drugs forTransthyretin Amyloid Cardiomyopathy Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Drugs forTransthyretin Amyloid Cardiomyopathy Distributors List
Table 59. Drugs forTransthyretin Amyloid Cardiomyopathy Customer List
Table 60. Global Drugs forTransthyretin Amyloid Cardiomyopathy SalesForecast by Region (2025-2030) & (K Units)
Table 61. Global Drugs forTransthyretin Amyloid Cardiomyopathy RevenueForecast by Region (2025-2030) & ($ millions)
Table 62. Americas Drugs forTransthyretin Amyloid Cardiomyopathy SalesForecast by Country (2025-2030) & (K Units)
Table 63. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 64. APAC Drugs forTransthyretin Amyloid Cardiomyopathy SalesForecast by Region (2025-2030) & (K Units)
Table 65. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 66. Europe Drugs forTransthyretin Amyloid Cardiomyopathy SalesForecast by Country (2025-2030) & (K Units)
Table 67. Europe Drugs forTransthyretin Amyloid Cardiomyopathy RevenueForecast by Country (2025-2030) & ($ millions)
Table 68. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy SalesForecast by Country (2025-2030) & (K Units)
Table 69. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy RevenueForecast by Country (2025-2030) & ($ millions)
Table 70. Global Drugs forTransthyretin Amyloid Cardiomyopathy SalesForecast byType (2025-2030) & (K Units)
Table 71. Global Drugs forTransthyretin Amyloid Cardiomyopathy RevenueForecast byType (2025-2030) & ($ millions)
Table 72. Global Drugs forTransthyretin Amyloid Cardiomyopathy SalesForecast by Application (2025-2030) & (K Units)
Table 73. Global Drugs forTransthyretin Amyloid Cardiomyopathy RevenueForecast by Application (2025-2030) & ($ millions)
Table 74. Pfizer Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 75. Pfizer Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 76. Pfizer Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 77. Pfizer Main Business
Table 78. Pfizer Latest Developments
Table 79.Teva Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 80.Teva Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 81.Teva Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 82.Teva Main Business
Table 83.Teva Latest Developments
Table 84. Avet Pharmaceuticals Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 85. Avet Pharmaceuticals Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 86. Avet Pharmaceuticals Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 87. Avet Pharmaceuticals Main Business
Table 88. Avet Pharmaceuticals Latest Developments
Table 89. Zydus Pharms Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 90. Zydus Pharms Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 91. Zydus Pharms Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 92. Zydus Pharms Main Business
Table 93. Zydus Pharms Latest Developments
Table 94. Alnylam Pharmaceuticals Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 95. Alnylam Pharmaceuticals Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 96. Alnylam Pharmaceuticals Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 97. Alnylam Pharmaceuticals Main Business
Table 98. Alnylam Pharmaceuticals Latest Developments
Table 99. AkceaTherapeutics Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 100. AkceaTherapeutics Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 101. AkceaTherapeutics Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 102. AkceaTherapeutics Main Business
Table 103. AkceaTherapeutics Latest Developments
Table 104. Ionis Pharmaceuticals Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 105. Ionis Pharmaceuticals Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 106. Ionis Pharmaceuticals Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 107. Ionis Pharmaceuticals Main Business
Table 108. Ionis Pharmaceuticals Latest Developments
Table 109. Qilu pharmaceutical Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 110. Qilu pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 111. Qilu pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 112. Qilu pharmaceutical Main Business
Table 113. Qilu pharmaceutical Latest Developments
Table 114. ChiaTaiTianqing Pharmaceutical Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 115. ChiaTaiTianqing Pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 116. ChiaTaiTianqing Pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 117. ChiaTaiTianqing Pharmaceutical Main Business
Table 118. ChiaTaiTianqing Pharmaceutical Latest Developments
Table 119. Luoxin Pharmaceutical Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 120. Luoxin Pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 121. Luoxin Pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 122. Luoxin Pharmaceutical Main Business
Table 123. Luoxin Pharmaceutical Latest Developments
Table 124. ZhengzhouTaifeng Pharmaceutical Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 125. ZhengzhouTaifeng Pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 126. ZhengzhouTaifeng Pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 127. ZhengzhouTaifeng Pharmaceutical Main Business
Table 128. ZhengzhouTaifeng Pharmaceutical Latest Developments
Table 129. Shapuaisi Pharma Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 130. Shapuaisi Pharma Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 131. Shapuaisi Pharma Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 132. Shapuaisi Pharma Main Business
Table 133. Shapuaisi Pharma Latest Developments
Table 134.Tonghua Zhongsheng Pharmaceutical Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 135.Tonghua Zhongsheng Pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 136.Tonghua Zhongsheng Pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 137.Tonghua Zhongsheng Pharmaceutical Main Business
Table 138.Tonghua Zhongsheng Pharmaceutical Latest Developments
LIST OFFIGURES
Figure 1. Picture of Drugs forTransthyretin Amyloid Cardiomyopathy
Figure 2. Drugs forTransthyretin Amyloid Cardiomyopathy Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Country/Region (2023)
Figure 10. Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture ofTransthyretinTetramer Stabilizer
Figure 12. Product Picture of RNA Interference
Figure 13. Product Picture of Antisense Oligonucleotides
Figure 14. Product Picture of Other
Figure 15. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share byType in 2023
Figure 16. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share byType (2019-2024)
Figure 17. Drugs forTransthyretin Amyloid Cardiomyopathy Consumed in Hospital and Clinic
Figure 18. Global Drugs forTransthyretin Amyloid Cardiomyopathy Market: Hospital and Clinic (2019-2024) & (K Units)
Figure 19. Drugs forTransthyretin Amyloid Cardiomyopathy Consumed in Retail Pharmacies
Figure 20. Global Drugs forTransthyretin Amyloid Cardiomyopathy Market: Retail Pharmacies (2019-2024) & (K Units)
Figure 21. Drugs forTransthyretin Amyloid Cardiomyopathy Consumed in Other
Figure 22. Global Drugs forTransthyretin Amyloid Cardiomyopathy Market: Other (2019-2024) & (K Units)
Figure 23. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sale Market Share by Application (2023)
Figure 24. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Application in 2023
Figure 25. Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Company in 2023 (K Units)
Figure 26. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Company in 2023
Figure 27. Drugs forTransthyretin Amyloid Cardiomyopathy Revenue by Company in 2023 ($ millions)
Figure 28. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Company in 2023
Figure 29. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Geographic Region (2019-2024)
Figure 30. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Geographic Region in 2023
Figure 31. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Sales 2019-2024 (K Units)
Figure 32. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Revenue 2019-2024 ($ millions)
Figure 33. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Sales 2019-2024 (K Units)
Figure 34. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Revenue 2019-2024 ($ millions)
Figure 35. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Sales 2019-2024 (K Units)
Figure 36. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Revenue 2019-2024 ($ millions)
Figure 37. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Sales 2019-2024 (K Units)
Figure 38. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Revenue 2019-2024 ($ millions)
Figure 39. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Country in 2023
Figure 40. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Country (2019-2024)
Figure 41. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share byType (2019-2024)
Figure 42. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Application (2019-2024)
Figure 43. United States Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 44. Canada Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 45. Mexico Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 46. Brazil Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 47. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Region in 2023
Figure 48. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Region (2019-2024)
Figure 49. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share byType (2019-2024)
Figure 50. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Application (2019-2024)
Figure 51. China Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 52. Japan Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 53. South Korea Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 54. Southeast Asia Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 55. India Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 56. Australia Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 57. ChinaTaiwan Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 58. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Country in 2023
Figure 59. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Country (2019-2024)
Figure 60. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share byType (2019-2024)
Figure 61. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Application (2019-2024)
Figure 62. Germany Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 63.France Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 64. UK Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 65. Italy Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 66. Russia Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 67. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Country (2019-2024)
Figure 68. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share byType (2019-2024)
Figure 69. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Application (2019-2024)
Figure 70. Egypt Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 71. South Africa Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 72. Israel Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 73.Turkey Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 74. GCC Countries Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Drugs forTransthyretin Amyloid Cardiomyopathy in 2023
Figure 76. Manufacturing Process Analysis of Drugs forTransthyretin Amyloid Cardiomyopathy
Figure 77. Industry Chain Structure of Drugs forTransthyretin Amyloid Cardiomyopathy
Figure 78. Channels of Distribution
Figure 79. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales MarketForecast by Region (2025-2030)
Figure 80. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market ShareForecast by Region (2025-2030)
Figure 81. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market ShareForecast byType (2025-2030)
Figure 82. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market ShareForecast byType (2025-2030)
Figure 83. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market ShareForecast by Application (2025-2030)
Figure 84. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market ShareForecast by Application (2025-2030)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Drugs for Transthyretin Amyloid Cardiomyopathy by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Drugs for Transthyretin Amyloid Cardiomyopathy by Country/Region, 2019, 2023 & 2030
2.2 Drugs for Transthyretin Amyloid Cardiomyopathy Segment by Type
2.2.1 Transthyretin Tetramer Stabilizer
2.2.2 RNA Interference
2.2.3 Antisense Oligonucleotides
2.2.4 Other
2.3 Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type
2.3.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Type (2019-2024)
2.3.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue and Market Share by Type (2019-2024)
2.3.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sale Price by Type (2019-2024)
2.4 Drugs for Transthyretin Amyloid Cardiomyopathy Segment by Application
2.4.1 Hospital and Clinic
2.4.2 Retail Pharmacies
2.4.3 Other
2.5 Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application
2.5.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sale Market Share by Application (2019-2024)
2.5.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue and Market Share by Application (2019-2024)
2.5.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Breakdown Data by Company
3.1.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Annual Sales by Company (2019-2024)
3.1.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sales Market Share by Company (2019-2024)
3.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Annual Revenue by Company (2019-2024)
3.2.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Company (2019-2024)
3.2.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Revenue Market Share by Company (2019-2024)
3.3 Global Drugs for Transthyretin Amyloid Cardiomyopathy Sale Price by Company
3.4 Key Manufacturers Drugs for Transthyretin Amyloid Cardiomyopathy Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Drugs for Transthyretin Amyloid Cardiomyopathy Product Location Distribution
3.4.2 Players Drugs for Transthyretin Amyloid Cardiomyopathy Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DRUGS FOR TRANSTHYRETIN AMYLOID CARDIOMYOPATHY BY GEOGRAPHIC REGION
4.1 World Historic Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Geographic Region (2019-2024)
4.1.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Drugs for Transthyretin Amyloid Cardiomyopathy Market Size by Country/Region (2019-2024)
4.2.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Annual Sales by Country/Region (2019-2024)
4.2.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Annual Revenue by Country/Region (2019-2024)
4.3 Americas Drugs for Transthyretin Amyloid Cardiomyopathy Sales Growth
4.4 APAC Drugs for Transthyretin Amyloid Cardiomyopathy Sales Growth
4.5 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales Growth
4.6 Middle East & Africa Drugs for Transthyretin Amyloid Cardiomyopathy Sales Growth
5 AMERICAS
5.1 Americas Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country
5.1.1 Americas Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2019-2024)
5.1.2 Americas Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country (2019-2024)
5.2 Americas Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2019-2024)
5.3 Americas Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region
6.1.1 APAC Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Region (2019-2024)
6.1.2 APAC Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Region (2019-2024)
6.2 APAC Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2019-2024)
6.3 APAC Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Drugs for Transthyretin Amyloid Cardiomyopathy by Country
7.1.1 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2019-2024)
7.1.2 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country (2019-2024)
7.2 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2019-2024)
7.3 Europe Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Drugs for Transthyretin Amyloid Cardiomyopathy by Country
8.1.1 Middle East & Africa Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Country (2019-2024)
8.1.2 Middle East & Africa Drugs for Transthyretin Amyloid Cardiomyopathy Revenue by Country (2019-2024)
8.2 Middle East & Africa Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Type (2019-2024)
8.3 Middle East & Africa Drugs for Transthyretin Amyloid Cardiomyopathy Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Drugs for Transthyretin Amyloid Cardiomyopathy
10.3 Manufacturing Process Analysis of Drugs for Transthyretin Amyloid Cardiomyopathy
10.4 Industry Chain Structure of Drugs for Transthyretin Amyloid Cardiomyopathy
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Drugs for Transthyretin Amyloid Cardiomyopathy Distributors
11.3 Drugs for Transthyretin Amyloid Cardiomyopathy Customer
12 WORLD FORECAST REVIEW FOR DRUGS FOR TRANSTHYRETIN AMYLOID CARDIOMYOPATHY BY GEOGRAPHIC REGION
12.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Market Size Forecast by Region
12.1.1 Global Drugs for Transthyretin Amyloid Cardiomyopathy Forecast by Region (2025-2030)
12.1.2 Global Drugs for Transthyretin Amyloid Cardiomyopathy Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Drugs for Transthyretin Amyloid Cardiomyopathy Forecast by Type (2025-2030)
12.7 Global Drugs for Transthyretin Amyloid Cardiomyopathy Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.1.3 Pfizer Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Teva
13.2.1 Teva Company Information
13.2.2 Teva Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.2.3 Teva Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Teva Main Business Overview
13.2.5 Teva Latest Developments
13.3 Avet Pharmaceuticals
13.3.1 Avet Pharmaceuticals Company Information
13.3.2 Avet Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.3.3 Avet Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Avet Pharmaceuticals Main Business Overview
13.3.5 Avet Pharmaceuticals Latest Developments
13.4 Zydus Pharms
13.4.1 Zydus Pharms Company Information
13.4.2 Zydus Pharms Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.4.3 Zydus Pharms Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Zydus Pharms Main Business Overview
13.4.5 Zydus Pharms Latest Developments
13.5 Alnylam Pharmaceuticals
13.5.1 Alnylam Pharmaceuticals Company Information
13.5.2 Alnylam Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.5.3 Alnylam Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Alnylam Pharmaceuticals Main Business Overview
13.5.5 Alnylam Pharmaceuticals Latest Developments
13.6 Akcea Therapeutics
13.6.1 Akcea Therapeutics Company Information
13.6.2 Akcea Therapeutics Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.6.3 Akcea Therapeutics Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Akcea Therapeutics Main Business Overview
13.6.5 Akcea Therapeutics Latest Developments
13.7 Ionis Pharmaceuticals
13.7.1 Ionis Pharmaceuticals Company Information
13.7.2 Ionis Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.7.3 Ionis Pharmaceuticals Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Ionis Pharmaceuticals Main Business Overview
13.7.5 Ionis Pharmaceuticals Latest Developments
13.8 Qilu pharmaceutical
13.8.1 Qilu pharmaceutical Company Information
13.8.2 Qilu pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.8.3 Qilu pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Qilu pharmaceutical Main Business Overview
13.8.5 Qilu pharmaceutical Latest Developments
13.9 Chia Tai Tianqing Pharmaceutical
13.9.1 Chia Tai Tianqing Pharmaceutical Company Information
13.9.2 Chia Tai Tianqing Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.9.3 Chia Tai Tianqing Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
13.9.5 Chia Tai Tianqing Pharmaceutical Latest Developments
13.10 Luoxin Pharmaceutical
13.10.1 Luoxin Pharmaceutical Company Information
13.10.2 Luoxin Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.10.3 Luoxin Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Luoxin Pharmaceutical Main Business Overview
13.10.5 Luoxin Pharmaceutical Latest Developments
13.11 Zhengzhou Taifeng Pharmaceutical
13.11.1 Zhengzhou Taifeng Pharmaceutical Company Information
13.11.2 Zhengzhou Taifeng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.11.3 Zhengzhou Taifeng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Zhengzhou Taifeng Pharmaceutical Main Business Overview
13.11.5 Zhengzhou Taifeng Pharmaceutical Latest Developments
13.12 Shapuaisi Pharma
13.12.1 Shapuaisi Pharma Company Information
13.12.2 Shapuaisi Pharma Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.12.3 Shapuaisi Pharma Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Shapuaisi Pharma Main Business Overview
13.12.5 Shapuaisi Pharma Latest Developments
13.13 Tonghua Zhongsheng Pharmaceutical
13.13.1 Tonghua Zhongsheng Pharmaceutical Company Information
13.13.2 Tonghua Zhongsheng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
13.13.3 Tonghua Zhongsheng Pharmaceutical Drugs for Transthyretin Amyloid Cardiomyopathy Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Tonghua Zhongsheng Pharmaceutical Main Business Overview
13.13.5 Tonghua Zhongsheng Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1. Drugs forTransthyretin Amyloid Cardiomyopathy Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Drugs forTransthyretin Amyloid Cardiomyopathy Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players ofTransthyretinTetramer Stabilizer
Table 4. Major Players of RNA Interference
Table 5. Major Players of Antisense Oligonucleotides
Table 6. Major Players of Other
Table 7. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales byType (2019-2024) & (K Units)
Table 8. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share byType (2019-2024)
Table 9. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue byType (2019-2024) & ($ million)
Table 10. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share byType (2019-2024)
Table 11. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sale Price byType (2019-2024) & (US$/Unit)
Table 12. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sale by Application (2019-2024) & (K Units)
Table 13. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sale Market Share by Application (2019-2024)
Table 14. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue by Application (2019-2024) & ($ million)
Table 15. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Application (2019-2024)
Table 16. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sale Price by Application (2019-2024) & (US$/Unit)
Table 17. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Company (2019-2024) & (K Units)
Table 18. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Company (2019-2024)
Table 19. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue by Company (2019-2024) & ($ millions)
Table 20. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Company (2019-2024)
Table 21. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sale Price by Company (2019-2024) & (US$/Unit)
Table 22. Key Manufacturers Drugs forTransthyretin Amyloid Cardiomyopathy Producing Area Distribution and Sales Area
Table 23. Players Drugs forTransthyretin Amyloid Cardiomyopathy Products Offered
Table 24. Drugs forTransthyretin Amyloid Cardiomyopathy Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Geographic Region (2019-2024) & (K Units)
Table 28. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share Geographic Region (2019-2024)
Table 29. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Geographic Region (2019-2024)
Table 31. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Country/Region (2019-2024) & (K Units)
Table 32. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Country/Region (2019-2024)
Table 33. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Country/Region (2019-2024)
Table 35. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Country (2019-2024) & (K Units)
Table 36. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Country (2019-2024)
Table 37. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Revenue by Country (2019-2024) & ($ millions)
Table 38. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Sales byType (2019-2024) & (K Units)
Table 39. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Application (2019-2024) & (K Units)
Table 40. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Region (2019-2024) & (K Units)
Table 41. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Region (2019-2024)
Table 42. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Revenue by Region (2019-2024) & ($ millions)
Table 43. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Sales byType (2019-2024) & (K Units)
Table 44. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Application (2019-2024) & (K Units)
Table 45. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Country (2019-2024) & (K Units)
Table 46. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Revenue by Country (2019-2024) & ($ millions)
Table 47. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Sales byType (2019-2024) & (K Units)
Table 48. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Application (2019-2024) & (K Units)
Table 49. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Country (2019-2024) & (K Units)
Table 50. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Country (2019-2024)
Table 51. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Sales byType (2019-2024) & (K Units)
Table 52. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Application (2019-2024) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Drugs forTransthyretin Amyloid Cardiomyopathy
Table 54. Key Market Challenges & Risks of Drugs forTransthyretin Amyloid Cardiomyopathy
Table 55. Key IndustryTrends of Drugs forTransthyretin Amyloid Cardiomyopathy
Table 56. Drugs forTransthyretin Amyloid Cardiomyopathy Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Drugs forTransthyretin Amyloid Cardiomyopathy Distributors List
Table 59. Drugs forTransthyretin Amyloid Cardiomyopathy Customer List
Table 60. Global Drugs forTransthyretin Amyloid Cardiomyopathy SalesForecast by Region (2025-2030) & (K Units)
Table 61. Global Drugs forTransthyretin Amyloid Cardiomyopathy RevenueForecast by Region (2025-2030) & ($ millions)
Table 62. Americas Drugs forTransthyretin Amyloid Cardiomyopathy SalesForecast by Country (2025-2030) & (K Units)
Table 63. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 64. APAC Drugs forTransthyretin Amyloid Cardiomyopathy SalesForecast by Region (2025-2030) & (K Units)
Table 65. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 66. Europe Drugs forTransthyretin Amyloid Cardiomyopathy SalesForecast by Country (2025-2030) & (K Units)
Table 67. Europe Drugs forTransthyretin Amyloid Cardiomyopathy RevenueForecast by Country (2025-2030) & ($ millions)
Table 68. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy SalesForecast by Country (2025-2030) & (K Units)
Table 69. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy RevenueForecast by Country (2025-2030) & ($ millions)
Table 70. Global Drugs forTransthyretin Amyloid Cardiomyopathy SalesForecast byType (2025-2030) & (K Units)
Table 71. Global Drugs forTransthyretin Amyloid Cardiomyopathy RevenueForecast byType (2025-2030) & ($ millions)
Table 72. Global Drugs forTransthyretin Amyloid Cardiomyopathy SalesForecast by Application (2025-2030) & (K Units)
Table 73. Global Drugs forTransthyretin Amyloid Cardiomyopathy RevenueForecast by Application (2025-2030) & ($ millions)
Table 74. Pfizer Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 75. Pfizer Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 76. Pfizer Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 77. Pfizer Main Business
Table 78. Pfizer Latest Developments
Table 79.Teva Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 80.Teva Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 81.Teva Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 82.Teva Main Business
Table 83.Teva Latest Developments
Table 84. Avet Pharmaceuticals Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 85. Avet Pharmaceuticals Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 86. Avet Pharmaceuticals Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 87. Avet Pharmaceuticals Main Business
Table 88. Avet Pharmaceuticals Latest Developments
Table 89. Zydus Pharms Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 90. Zydus Pharms Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 91. Zydus Pharms Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 92. Zydus Pharms Main Business
Table 93. Zydus Pharms Latest Developments
Table 94. Alnylam Pharmaceuticals Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 95. Alnylam Pharmaceuticals Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 96. Alnylam Pharmaceuticals Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 97. Alnylam Pharmaceuticals Main Business
Table 98. Alnylam Pharmaceuticals Latest Developments
Table 99. AkceaTherapeutics Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 100. AkceaTherapeutics Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 101. AkceaTherapeutics Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 102. AkceaTherapeutics Main Business
Table 103. AkceaTherapeutics Latest Developments
Table 104. Ionis Pharmaceuticals Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 105. Ionis Pharmaceuticals Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 106. Ionis Pharmaceuticals Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 107. Ionis Pharmaceuticals Main Business
Table 108. Ionis Pharmaceuticals Latest Developments
Table 109. Qilu pharmaceutical Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 110. Qilu pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 111. Qilu pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 112. Qilu pharmaceutical Main Business
Table 113. Qilu pharmaceutical Latest Developments
Table 114. ChiaTaiTianqing Pharmaceutical Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 115. ChiaTaiTianqing Pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 116. ChiaTaiTianqing Pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 117. ChiaTaiTianqing Pharmaceutical Main Business
Table 118. ChiaTaiTianqing Pharmaceutical Latest Developments
Table 119. Luoxin Pharmaceutical Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 120. Luoxin Pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 121. Luoxin Pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 122. Luoxin Pharmaceutical Main Business
Table 123. Luoxin Pharmaceutical Latest Developments
Table 124. ZhengzhouTaifeng Pharmaceutical Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 125. ZhengzhouTaifeng Pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 126. ZhengzhouTaifeng Pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 127. ZhengzhouTaifeng Pharmaceutical Main Business
Table 128. ZhengzhouTaifeng Pharmaceutical Latest Developments
Table 129. Shapuaisi Pharma Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 130. Shapuaisi Pharma Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 131. Shapuaisi Pharma Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 132. Shapuaisi Pharma Main Business
Table 133. Shapuaisi Pharma Latest Developments
Table 134.Tonghua Zhongsheng Pharmaceutical Basic Information, Drugs forTransthyretin Amyloid Cardiomyopathy Manufacturing Base, Sales Area and Its Competitors
Table 135.Tonghua Zhongsheng Pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Product Portfolios and Specifications
Table 136.Tonghua Zhongsheng Pharmaceutical Drugs forTransthyretin Amyloid Cardiomyopathy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 137.Tonghua Zhongsheng Pharmaceutical Main Business
Table 138.Tonghua Zhongsheng Pharmaceutical Latest Developments
LIST OFFIGURES
Figure 1. Picture of Drugs forTransthyretin Amyloid Cardiomyopathy
Figure 2. Drugs forTransthyretin Amyloid Cardiomyopathy Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Country/Region (2023)
Figure 10. Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture ofTransthyretinTetramer Stabilizer
Figure 12. Product Picture of RNA Interference
Figure 13. Product Picture of Antisense Oligonucleotides
Figure 14. Product Picture of Other
Figure 15. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share byType in 2023
Figure 16. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share byType (2019-2024)
Figure 17. Drugs forTransthyretin Amyloid Cardiomyopathy Consumed in Hospital and Clinic
Figure 18. Global Drugs forTransthyretin Amyloid Cardiomyopathy Market: Hospital and Clinic (2019-2024) & (K Units)
Figure 19. Drugs forTransthyretin Amyloid Cardiomyopathy Consumed in Retail Pharmacies
Figure 20. Global Drugs forTransthyretin Amyloid Cardiomyopathy Market: Retail Pharmacies (2019-2024) & (K Units)
Figure 21. Drugs forTransthyretin Amyloid Cardiomyopathy Consumed in Other
Figure 22. Global Drugs forTransthyretin Amyloid Cardiomyopathy Market: Other (2019-2024) & (K Units)
Figure 23. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sale Market Share by Application (2023)
Figure 24. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Application in 2023
Figure 25. Drugs forTransthyretin Amyloid Cardiomyopathy Sales by Company in 2023 (K Units)
Figure 26. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Company in 2023
Figure 27. Drugs forTransthyretin Amyloid Cardiomyopathy Revenue by Company in 2023 ($ millions)
Figure 28. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Company in 2023
Figure 29. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Geographic Region (2019-2024)
Figure 30. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Geographic Region in 2023
Figure 31. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Sales 2019-2024 (K Units)
Figure 32. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Revenue 2019-2024 ($ millions)
Figure 33. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Sales 2019-2024 (K Units)
Figure 34. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Revenue 2019-2024 ($ millions)
Figure 35. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Sales 2019-2024 (K Units)
Figure 36. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Revenue 2019-2024 ($ millions)
Figure 37. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Sales 2019-2024 (K Units)
Figure 38. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Revenue 2019-2024 ($ millions)
Figure 39. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Country in 2023
Figure 40. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Country (2019-2024)
Figure 41. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share byType (2019-2024)
Figure 42. Americas Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Application (2019-2024)
Figure 43. United States Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 44. Canada Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 45. Mexico Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 46. Brazil Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 47. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Region in 2023
Figure 48. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Region (2019-2024)
Figure 49. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share byType (2019-2024)
Figure 50. APAC Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Application (2019-2024)
Figure 51. China Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 52. Japan Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 53. South Korea Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 54. Southeast Asia Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 55. India Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 56. Australia Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 57. ChinaTaiwan Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 58. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Country in 2023
Figure 59. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market Share by Country (2019-2024)
Figure 60. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share byType (2019-2024)
Figure 61. Europe Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Application (2019-2024)
Figure 62. Germany Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 63.France Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 64. UK Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 65. Italy Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 66. Russia Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 67. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Country (2019-2024)
Figure 68. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share byType (2019-2024)
Figure 69. Middle East & Africa Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market Share by Application (2019-2024)
Figure 70. Egypt Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 71. South Africa Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 72. Israel Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 73.Turkey Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 74. GCC Countries Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Growth 2019-2024 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Drugs forTransthyretin Amyloid Cardiomyopathy in 2023
Figure 76. Manufacturing Process Analysis of Drugs forTransthyretin Amyloid Cardiomyopathy
Figure 77. Industry Chain Structure of Drugs forTransthyretin Amyloid Cardiomyopathy
Figure 78. Channels of Distribution
Figure 79. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales MarketForecast by Region (2025-2030)
Figure 80. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market ShareForecast by Region (2025-2030)
Figure 81. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market ShareForecast byType (2025-2030)
Figure 82. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market ShareForecast byType (2025-2030)
Figure 83. Global Drugs forTransthyretin Amyloid Cardiomyopathy Sales Market ShareForecast by Application (2025-2030)
Figure 84. Global Drugs forTransthyretin Amyloid Cardiomyopathy Revenue Market ShareForecast by Application (2025-2030)
